Table 4: Comparison of SVR and non-SVR patients treated with peginterferon and ribavirin by univariate analysis (a) and multivariate analysis (b).
(a) Univariate analysis

SVR, Non-SVR, values (SVR versus non-SVR groups)

Gender, male/female39/3334/400.40
Age, years54.4 ± 12.757.0 ± 9.30.15
Previous treatment: naïve/relapse/null59/12/143/14/170.00020
AST, IU/L54.1 ± 54.361.8 ± 42.50.34
ALT, IU/L69.0 ± 71.573.0 ± 58.20.71
γ-GTP, IU/L42.7 ± 41.370.0 ± 85.70.0158
Hemoglobin, g/dL13.9 ± 1.114.1 ± 1.30.31
Platelets, ×104/mm317.8 ± 5.415.7 ± 5.90.0265
Treatment response
 RVR, 1500.000107
 EVR, 5312<0.0001
 IFNL4, ss469415590,
major/minor/ND
60/10/233/38/3<0.0001

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.
(b) Factors associated with SVR among patients treated with peginterferon plus ribavirin by multivariate analysis

FactorCategoryOdds ratio95% CI values

IFNL4, ss469415590major/minor2.561.005–6.5570.0486
EVR+/−10.164.28–24.10<0.0001

EVR: early virological response.